Orthopediatrics Corp. (KIDS)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 1425450 · fiscal year ends in Dec
Closing price $31.49 on 29 Oct 2026; 52-week range $14.64 to $31.49.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $264.1M
- Revenue growth
- 16.1%
- Net income, last twelve months
- -$33.9M
- Earnings per share
- -$1.43
- Gross margin
- 73.8%
- Operating margin
- -9.4%
- Net margin
- -12.8%
- Free cash flow
- $3.2M
- Return on equity
- -10.0%
- Market value
- $822.2M
- Cash
- $17.1M
- Debt
- $104.6M
- Debt to equity
- 0.31
- Shares outstanding
- 26.1M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $236.3M | -$39.2M | -$39.6M | -$1.69 | -$16.0M | 10-K filed 4 Mar 2026 |
| FY2024 | 31 Dec 2024 | $204.7M | -$35.0M | -$37.8M | -$1.64 | -$41.3M | 10-K filed 5 Mar 2025 |
| FY2023 | 31 Dec 2023 | $148.7M | -$26.8M | -$21.0M | -$0.92 | -$43.9M | 10-K filed 8 Mar 2024 |
| FY2022 | 31 Dec 2022 | $122.3M | -$25.4M | $1.3M | $0.06 | -$31.8M | 10-K filed 1 Mar 2023 |
| FY2021 | 31 Dec 2021 | $98.0M | -$18.0M | -$16.3M | -$0.84 | -$21.2M | 10-K filed 3 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sep 2026 | $72.7M | -$5.9M | -$0.25 |
| Q2 FY2026 | 30 Jun 2026 | $70.5M | -$7.2M | -$0.30 |
| Q1 FY2026 | 31 Mar 2026 | $59.4M | -$10.7M | -$0.45 |
| Q4 FY2025 | 31 Dec 2025 | $61.6M | -$10.1M | -$0.43 |
| Q3 FY2025 | 30 Sep 2025 | $61.3M | -$11.8M | -$0.50 |
| Q2 FY2025 | 30 Jun 2025 | $61.1M | -$7.1M | -$0.30 |
| Q1 FY2025 | 31 Mar 2025 | $52.4M | -$10.7M | -$0.46 |
| Q4 FY2024 | 31 Dec 2024 | $52.7M | -$16.1M | -$0.69 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Trauma and deformity | $166.3M | 70.4% |
| Scoliosis | $66.0M | 27.9% |
| Sports medicine/other | $4.0M | 1.7% |
By region, FY2025
| Segment | Revenue | Share |
|---|---|---|
| United States | $186.4M | 78.9% |
| International | $49.9M | 21.1% |
Company events
The newest 8-K filings of 154 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 27 Oct 2026 | 8-K | Investor update | 7.01, 9.01 |
| 27 Oct 2026 | 8-K | Results | 2.02, 9.01 |
| 4 Aug 2026 | 8-K | Investor update | 7.01, 9.01 |
| 4 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 4 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 30 Apr 2026 | 8-K | Investor update | 7.01, 9.01 |
| 30 Apr 2026 | 8-K | Results | 2.02, 9.01 |
| 1 Apr 2026 | 8-K | Material agreement, New debt | 1.01, 2.03, 9.01 |
| 26 Feb 2026 | 8-K | Investor update | 7.01, 9.01 |
| 26 Feb 2026 | 8-K | Results | 2.02, 9.01 |
| 12 Jan 2026 | 8-K | Investor update | 7.01, 9.01 |
| 12 Jan 2026 | 8-K | Results | 2.02, 9.01 |
Every filing
The newest filings with the SEC of 271 held.
| Filed | Form | Period |
|---|---|---|
| 28 Oct 2026 | 10-Q | 30 Sep 2026 |
| 27 Oct 2026 | 8-K | 27 Oct 2026 |
| 27 Oct 2026 | 8-K | 27 Oct 2026 |
| 5 Aug 2026 | 10-Q | 30 Jun 2026 |
| 4 Aug 2026 | 8-K | 4 Aug 2026 |
| 4 Aug 2026 | 8-K | 4 Aug 2026 |
| 4 Jun 2026 | 8-K | 4 Jun 2026 |
| 1 May 2026 | 10-Q | 31 Mar 2026 |
| 30 Apr 2026 | 8-K | 30 Apr 2026 |
| 30 Apr 2026 | 8-K | 30 Apr 2026 |
| 20 Apr 2026 | ARS | 31 Dec 2025 |
| 20 Apr 2026 | DEFA14A | – |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 10 Sep 2026 | Squadron Capital Llc, 10% owner | Sale outside a trading plan | 302,369 | $21.01 | $6.4M | 6,201,764 | 11 Sep 2026 |
| 10 Sep 2026 | Pritzker Jennifer N., 10% owner | Sale outside a trading plan | 302,369 | $21.01 | $6.4M | 6,201,764 | 11 Sep 2026 |
| 10 Sep 2026 | Pelizzon David R, Director | Sale outside a trading plan | 302,369 | $21.01 | $6.4M | 6,201,764 | 10 Sep 2026 |
| 2 Sep 2026 | Squadron Capital Llc, 10% owner | Sale outside a trading plan | 22,500 | $23.35 | $525.4K | 6,504,133 | 4 Sep 2026 |
| 2 Sep 2026 | Pritzker Jennifer N., 10% owner | Sale outside a trading plan | 22,500 | $23.35 | $525.4K | 6,504,133 | 4 Sep 2026 |
| 2 Sep 2026 | Pelizzon David R, Director | Sale outside a trading plan | 22,500 | $23.35 | $525.4K | 6,504,133 | 4 Sep 2026 |
| 1 Sep 2026 | Squadron Capital Llc, 10% owner | Sale outside a trading plan | 10,131 | $23.10 | $234.0K | 6,526,633 | 1 Sep 2026 |
| 1 Sep 2026 | Pritzker Jennifer N., 10% owner | Sale outside a trading plan | 10,131 | $23.10 | $234.0K | 6,526,633 | 1 Sep 2026 |
| 1 Sep 2026 | Pelizzon David R, Director | Sale outside a trading plan | 10,131 | $23.10 | $234.0K | 6,526,633 | 1 Sep 2026 |
| 28 Aug 2026 | Squadron Capital Llc, 10% owner | Sale outside a trading plan | 326,700 | $23.04 | $7.5M | 6,536,764 | 1 Sep 2026 |
| 28 Aug 2026 | Pritzker Jennifer N., 10% owner | Sale outside a trading plan | 326,700 | $23.04 | $7.5M | 6,536,764 | 1 Sep 2026 |
| 28 Aug 2026 | Pelizzon David R, Director | Sale outside a trading plan | 326,700 | $23.04 | $7.5M | 6,536,764 | 1 Sep 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 24 Aug 2026 | Squadron Capital, LLC, 10% Stockholder | 700,000 | $18.4M | 24 Aug 2026 |
| 16 Mar 2026 | Odle Gregory A, Officer | 8,433 | $145.5K | 16 Mar 2026 |
| 16 Mar 2026 | Hauser Joseph W, Officer | 8,596 | $148.3K | 16 Mar 2026 |
| 16 Mar 2026 | Gerritzen Daniel J, Officer | 8,614 | $148.6K | 16 Mar 2026 |
| 16 Mar 2026 | Hite Fred, Officer | 12,993 | $224.2K | 16 Mar 2026 |
| 16 Mar 2026 | Bailey David R, Officer | 19,535 | $337.1K | 16 Mar 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 11 Sep 2026 | Squadron Capital LLC | 13D amended | 23.9% | 6.2M |
| 1 Sep 2026 | Squadron Capital LLC | 13D amended | 25.2% | 6.6M |
| 15 Jul 2026 | Integrated Core Strategies (US) LLC | 13G amended | 3.2% | 816.8K |
| 12 Nov 2025 | Brown Capital Management, LLC | 13G amended | 4.31% | 1.1M |
| 4 Nov 2025 | Integrated Core Strategies (US) LLC | 13G | 5.5% | 1.4M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 977.3K | +5.09% | 4.8 |
| 30 Sep 2026 | 930.0K | +5.88% | 5.54 |
| 15 Sep 2026 | 878.3K | +8.9% | 4.7 |
| 31 Aug 2026 | 806.5K | -5.3% | 3.02 |
| 14 Aug 2026 | 851.6K | +1.49% | 2.92 |
| 31 Jul 2026 | 839.1K | -4.78% | 5.9 |
| 15 Jul 2026 | 881.3K | -1.59% | 6.2 |
| 30 Jun 2026 | 895.5K | +5.45% | 4.93 |
Funds that hold it
From each fund's latest Form 13F.
136 funds held it at 30 Jun 2026: 64 added and 32 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Brown Advisory Inc. | 1,678,983 | $32.1M | +160,965 |
| BlackRock, Inc. | 1,272,714 | $24.3M | +98,668 |
| Braidwell LP | 1,100,370 | $21.1M | 0 |
| Granahan Investment Management, LLC | 1,085,964 | $20.8M | +189,223 |
| Millennium Management LLC | 816,830 | $15.6M | -420,069 |
| Wellington Management Group LLP | 794,309 | $15.2M | -93,135 |
| Vanguard Capital Management LLC | 755,624 | $14.5M | +37,448 |
| Soleus Capital Management, L.P. | 732,144 | $14.0M | +116,697 |
| Morgan Stanley | 693,387 | $13.3M | -447,731 |
| Wasatch Advisors LP | 515,677 | $9.9M | +186,357 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $25.8B, market value $119.5B
- 3M Co. (MMM): revenue $25.2B, market value $91.6B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $61.9B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $54.0B
- Resmed Inc. (RMD): revenue $5.7B, market value $35.5B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $29.8B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $29.1B
- Medline Inc. (MDLN): revenue –, market value $27.5B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.3B
- Solventum Corp. (SOLV): revenue $8.3B, market value $14.2B